Common Contracts
2 similar Securities Purchase Agreement contracts by Poseida Therapeutics, Inc., Taysha Gene Therapies, Inc.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 7th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is being entered into as of August 4, 2023, by and between Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 9390 Towne Centre Drive, Suite 200, San Diego, California 92121 and Astellas US, LLC, a Delaware limited liability company (the “Purchaser”) with its principal place of business at 2375 Waterview Drive, Northbrook, IL 60062. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas, Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware corporation (the “Purchaser”) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
